{"links":{"html":"https://www.erudio.com/reports/atalante-nct02891824","json":"https://www.erudio.com/reports/atalante-nct02891824.json","markdown":"https://www.erudio.com/reports/atalante-nct02891824.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"atalante-02891824"}},"request":"https://www.erudio.com/contact?report=atalante-02891824"},"offer":{"cited_commentary_sources":16,"verified_hcp_statements":50,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"atalante-nct02891824"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=atalante-02891824","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/atalante-nct02891824","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T00:33:44.295060Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: per-finding counts; the sample findings; the report description. The trial's name is spelled as its investigators write it, “ATALANTE” (NCT02891824), outside quotations (was “ATALANT”, “ATALANTA”, “Atalanta”). An editorial bracket follows a transcription-garbled trial name in quotations: “Atalanta [ATALANTE]”."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":4},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1"},{"claim_count":12,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":9,"title":"Secondary endpoint: Efficacy: Overall survival (OS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Efficacy: Time from date randomization to second subsequent therapy or date of death (TSST) whichever come first"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: patient reported outcome variables"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":0,"title":"Secondary endpoint: Adverse events"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":4,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T8","registry_field":"outcomesModule","source_count":0,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":5,"title":"Clinical importance, routine-use implications and market expectations"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":2,"title":"Predictive markers and biopsy-led translational research"},{"claim_count":8,"coverage":"discussed","id":"A3","source_count":7,"title":"Combination rationale and accumulated disappointment with checkpoint inhibition"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":1,"title":"AGO-OVAR 2.29/ENGOT-ov34 comparison and alternative immune research approaches"}],"counts":{"cited_sources":17,"claims_by_expression_type":{"comparison":5,"experience":1,"interpretation":20,"opinion":10,"primary_context":3,"question":1,"restatement":6,"uncertainty":2,"unspecified":2},"claims_by_kind":{"objective_result":2,"protocol_statement":1,"publication_statement":17,"source_observation":30},"clinician_statements":1,"evidence_units":38,"findings":4,"organisational_accounts":3,"people_cited":9,"people_identity_verified":5,"people_total":9,"screened_sources":40,"verified_claims":50},"findings_index":[{"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":10},"ma_question":true,"named_voices":6,"passages":8,"sources":7,"sources_by_kind":{"commentary":3,"media":3,"publication":1}},"title":"Exploratory OS: clinical importance and implications for routine use"},{"id":"F2","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":4,"views":8},"has_counterview":true,"limitations":3,"links":{"context":0,"support":12},"ma_question":true,"named_voices":4,"passages":8,"sources":6,"sources_by_kind":{"commentary":4,"media":1,"publication":1}},"title":"Maturity and hierarchical testing frame the dispute over how OS should be interpreted"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":0,"views":6},"has_counterview":false,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":6,"sources":3,"sources_by_kind":{"media":2,"publication":1}},"title":"Subgroup hints, PD-L1 findings and the search for patient selection"},{"id":"F4","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":4,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":7,"passages":12,"sources":9,"sources_by_kind":{"commentary":6,"media":2,"publication":1}},"title":"Reactions to repeated negative studies and proposed immune research directions"}],"medical_affairs_question":"How should Medical Affairs explain patient-relevant exploratory OS without implying confirmatory efficacy, routine checkpoint-inhibitor use or validated patient selection?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinical importance and routine-use implications of exploratory OS"},{"id":"section-2","level":2,"title":"Maturity and hierarchy shape the OS controversy"},{"id":"section-3","level":2,"title":"PD-L1, clinical-subgroup hints and translational research"},{"id":"section-4","level":2,"title":"Repeated negative studies and proposed immune research directions"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":8}],"id":"T2","label":"Secondary endpoint: Efficacy: Overall survival (OS)"},{"findings":[],"id":"T3","label":"Secondary endpoint: Efficacy: Time from date randomization to second subsequent therapy or date of death (TSST) whichever come first"},{"findings":[],"id":"T4","label":"Secondary endpoint: patient reported outcome variables"},{"findings":[],"id":"T5","label":"Secondary endpoint: Adverse events"},{"findings":[{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F4","shared_claims":4}],"id":"T7","label":"The comparison"},{"findings":[],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T00:33:44.295060Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T00:51:54Z","record_hash":"f9c78f9c5cf618557fcca498be95053c9e3569e026e6b195c36bc7bef03b72ab","release_hash":"0c28fdeb00a949052b3838d8799c0bd4a4997e624d5ac012e7b9ee6f7b534e3b","report_id":"erudio-nct02891824","run_id":"28497707-5c68-40c4-a2a1-3ec6e30fec8f","schema_version":"5.0","slug":"atalante-02891824","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"ATALANTE asks whether adding atezolizumab to platinum chemotherapy plus bevacizumab can delay progression in platinum-sensitive recurrent ovarian cancer. Commentary comes from X posts and video interviews on X and YouTube. Debate centers on how survival-data maturity and hierarchical testing frame contested interpretation of exploratory overall survival and its implications for routine atezolizumab use. Selection of patients for immunotherapy in this setting remains unresolved.","meta_description":"40 sources screened · 50 verified statements (1 from clinicians verified by NPI or staff page) from 17 sources · 4 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-12ca41d49508e4af093f","claim-687426de6fd773e9b33d"],"id":"F2","paraphrase":"A YouTube interview addresses how to interpret overall survival in relation to follow-up and the trial’s endpoint-testing plan.","source_channel":"youtube","source_date":"2024-10-23","title":"Maturity and hierarchical testing frame the dispute over how OS should be interpreted"}]},"publication":{"approved_at":"2026-10-31T00:51:54Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-31T02:18:02Z","summary":"Corrected to match the delivered report: per-finding counts; the sample findings; the report description. The trial's name is spelled as its investigators write it, “ATALANTE” (NCT02891824), outside quotations (was “ATALANT”, “ATALANTA”, “Atalanta”). An editorial bracket follows a transcription-garbled trial name in quotations: “Atalanta [ATALANTE]”."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":40},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources include organizational accounts and relayed article or presentation wording. Repetition and reposting do not establish independent HCP agreement.","Clinical roles are not established for every named social-media author. Account names are not treated as proof of credentials or specialty.","The speaker of the relevant AGO229-ENGOT-ov34 interview passages cannot be named from the available speech; publisher identification alone does not establish who said those words.","The full final-OS report was not available for assessment. Later survival findings are described through posts and interviews, while the available results publication reports earlier, immature OS.","A separate protocol and exact regulatory labels for the studied combinations were not available in the sources reviewed. A speaker's expectation about market entry is not an established regulatory outcome.","No HCP commentary on TSST, patient-reported outcomes, adverse-event interpretation or tolerability was identified in the assessed material. This absence does not establish an absence of clinical concern."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":1,"registry":0,"regulatory":0,"x_thread":12,"x_video":1,"youtube":3},"by_evidence_role":{"commentary":16,"results":1},"count":17,"evidence_window":{"end":"2026-10-14","start":"2022-09-09"},"retrieval_snapshot":"2026-10-30T23:57:34.379596Z","timeline":[{"count":3,"week":"2022-W36"},{"count":1,"week":"2023-W36"},{"count":1,"week":"2023-W42"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":3,"week":"2024-W37"},{"count":2,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W42"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT02891824:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT02891824:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:37643382","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-gudczoxomvaeynwdtqssqyap-3mssoap2uhe2l","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:de5801","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568226843093868546:6c7c5959-efff-46bc-aade-16efa4f3bcdb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568237948004335619:c5f97901-eed6-45f4-af7e-aa40d84271ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568246042696585219:ad0acb5a-8cd7-4b24-8e8f-1fe403854042","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568259923913461763:926d91bf-cea5-4aa3-9bb2-caea587ae028","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568399637756743683:b1b4fa69-e16f-43dc-bcf3-b9fe81c0c011","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1621826679713718272:5b552060-0424-44e8-ac04-c2b097d808fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696627921408917966:9b114701-efb0-4276-a323-1dad6d093f63","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696733737067991107:eb72dea1-3dcf-477a-aeef-3807eb32b80d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696738743934173383:0dfd4073-a214-4326-9912-806cd3991426","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696938493149151577:0b3aab0f-5cf9-4e08-8103-01a9547d876c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1696946473240252584:f38b3b70-7218-4b31-98ed-08c453301ea5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1697512773758955802:da2a3c53-fedd-44c5-be52-2cf52c36859d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1697542221443072440:ce9c8556-88da-4d1e-a868-33f11a5addf8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1697640461148508604:6a236d35-d834-4b78-855a-1cbebf79b613","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1699541612408213778:8c3f0fdb-010f-4df5-8558-f56df112555b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1701641897003860082:5a22ffba-87ea-4594-befd-d6abfae0ad58","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1703197154485944817:ec51ea13-8757-4cbb-84df-e8e644e9d4aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1715337087929532558:c1dd674f-8673-4629-ba0b-ad598931b0df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1716862113879372261:d6617413-e099-42d2-828a-90614ccc458e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1717873370925076642:e732820a-963f-45e0-944c-37225f220ef7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1718924238030053732:8a8ce4ea-ddd1-4871-9c6a-9972dc3bdc77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1746969033226723695:0b1ebd30-97b9-4d5b-9e5f-050bfe28c58f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1797262345837641828:ed95b479-417f-4621-b03f-b8991706cd48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1813171245925507218:64cf8538-a621-49ea-b211-8c62a2d1b285","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835215385110401218:fb7e3e0b-1aad-4c9d-9744-6a51d2e2220d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835215711884517537:c630e3f5-42a1-4a8e-9c6c-8c68c882f3d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835255325991071982:276ec41a-dcf0-489a-8124-9eccaa6230b9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835559090371650031:5634f5e6-e61a-43da-9912-a5456fc9571f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1851556156684079500:5a8e442c-8649-4ef1-b0de-80ab3d98a260","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082298581755785630:5a94acf8-4d7d-40c5-8ab4-85ce15d33f94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082438434958807393:27385d1b-a68e-465d-a70c-9cbe992a4056","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082813582215872715:584309f4-a291-4451-b23b-bf6dbd98a908","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2087162197499683290:154890b0-2513-4f12-a0ce-748dfeaad7d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2110259829432373537:424ab4a3-524c-42b3-89cf-7d9b2979571b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:1851556156684079500","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:3-BQu7zItYo","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ID-To4pxZnY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:hgkqSV69c4w","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":34,"x_video":1,"youtube":3},"by_evidence_role":{"commentary":40},"count":40,"evidence_window":{"end":"2026-10-14","start":"2022-09-09"},"retrieval_snapshot":"2026-10-30T23:57:34.379596Z","timeline":[{"count":5,"week":"2022-W36"},{"count":1,"week":"2023-W05"},{"count":8,"week":"2023-W35"},{"count":1,"week":"2023-W36"},{"count":2,"week":"2023-W37"},{"count":1,"week":"2023-W42"},{"count":2,"week":"2023-W43"},{"count":1,"week":"2023-W44"},{"count":1,"week":"2024-W03"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W29"},{"count":3,"week":"2024-W37"},{"count":1,"week":"2024-W38"},{"count":2,"week":"2024-W43"},{"count":2,"week":"2024-W44"},{"count":1,"week":"2025-W26"},{"count":3,"week":"2026-W31"},{"count":2,"week":"2026-W33"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: atezolizumab + avastin + platinum-based chemotherapy","status":"unmapped"},{"reason":"Unmapped registry intervention: placebo + avastin + platinum-based chemotherapy","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Ovarian cancer","slug":"ovarian-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ATALANTE","aliases":["ATALANTE","ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab"],"brief_title":"ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab","collaborators":["Hoffmann-La Roche"],"conditions":["Ovarian Cancer"],"display_condition":"platinum-sensitive ovarian cancer","display_interventions":[["atezolizumab","bevacizumab"]],"enrollment":{"count":614,"type":"ACTUAL"},"interventions":[{"name":"atezolizumab + avastin + platinum-based chemotherapy","synonyms":["Tecentriq"],"type":"DRUG"},{"name":"placebo + avastin + platinum-based chemotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT02891824","official_title":"A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab","other_names":[{"kind":"also","name":"ENGOT-ov29"}],"overall_status":"COMPLETED","phase":["PHASE3"],"primary_completion_date":{"date":"2021-10-15","type":"ACTUAL"},"primary_endpoints":[{"measure":"Efficacy: Progression free survival, where the date of progression is based on investigator assessment using the RECIST version 1.1","timeFrame":"An average of 19 months"}],"registered_date":{"date":"2016-09-08","type":"ESTIMATED"},"registry_last_updated":"2025-02-11","registry_url":"https://clinicaltrials.gov/study/NCT02891824","short_name":"ATALANTE","short_name_basis":"registry_acronym","sponsor":"ARCAGY/ GINECO GROUP","start_date":{"date":"2016-09-22","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"GINECO-OV236b","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}